Article Figures & Data
Figures
- FIGURE 1.
Biodistribution data obtained 20 h after intravenous injection of 111In-octreotide in rats. Groups of 4 rats received 0.5 mL of PBS, 0.5 mL of lysine (80 mg), or 0.5 mL of Gelofusine (20 mg) intravenously 2–5 min before injection of 111In-octreotide. Results are presented as mean %ID/g; error bars indicate SDs. **P < 0.01.
- FIGURE 2.
Biodistribution data obtained with various plasma expanders 20 h after intravenous injection of 111In-octreotide in rats. Rats received PBS, lysine (80 mg), Gelofusine (20 mg), Voluven (20 mg), Rheomacrodex (30 mg), or Haemaccel (17.5 mg) (0.5 mL intravenously) 2–5 min before injection of 111In-octreotide. Results are presented as mean %ID/g; error bars indicate SDs. *P < 0.05. **P < 0.01.
- FIGURE 3.
111In-Octreotide uptake in kidneys of rats (4 per group) 20 h after injection. Rats received PBS or Gelofusine (20 mg) (0.5 mL intravenously) 3, 15, or 60 min before injection of 111In-octreotide. Results are presented as mean %ID/g; error bars indicate SDs. *P < 0.05. **P < 0.01.
Tables
Mean ± SD %ID/g in: Rats Mice Organ PBS Lysine Gelofusine PBS Lysine Gelofusine Blood 0.01 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.02 ± 0.01 0.02 ± 0.00 0.03 ± 0.00 Muscle 0.005 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 Lungs 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.59 ± 0.12 0.79 ± 0.25 0.69 ± 0.10 Spleen 0.04 ± 0.00 0.03 ± 0.00 0.05 ± 0.01 0.10 ± 0.01 0.08 ± 0.06 0.11 ± 0.01 Kidneys 1.36 ± 0.14 0.88 ± 0.08† 0.73 ± 0.15† 1.47 ± 0.38 1.23 ± 0.19‡ 0.58 ± 0.23† Adrenal glands 0.72 ± 0.20 0.69 ± 0.27 0.97 ± 0.30 0.13 ± 0.01 0.12 ± 0.03 0.18 ± 0.04 Pancreas 0.39 ± 0.05 0.27 ± 0.05‡ 0.40 ± 0.05 0.08 ± 0.01 0.08 ± 0.01 0.08 ± 0.02 Liver 0.04 ± 0.01 0.03 ± 0.01 0.04 ± 0.00 0.10 ± 0.01 0.10 ± 0.02 0.11 ± 0.02 Intestine 0.06 ± 0.03 0.08 ± 0.05 0.06 ± 0.04 0.09 ± 0.02 0.10 ± 0.02 0.11 ± 0.02 ↵* PBS, lysine, or Gelofusine was injected 2–5 min before injection of radiolabel. Biodistribution data were collected at 20 h after intravenous injection of 111In-octreotide in rats or mice. Groups of 4 rats received 0.5 mL of PBS or Gelofusine (20 mg). Groups of 5 mice received 0.1 mL of PBS or Gelofusine (4 mg).
↵† P < 0.01.
↵‡ P < 0.05.
Jump to section
Related Articles
Cited By...
- Gelofusine Ameliorates Colistin-Induced Nephrotoxicity
- SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
- Renal Handling of Circulating and Renal-Synthesized Hepcidin and Its Protective Effects against Hemoglobin-Mediated Kidney Injury
- Immuno-PET Imaging of Engineered Human T Cells in Tumors
- Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
- Synthesis and In Vitro and In Vivo Evaluation of Hypoxia-Enhanced 111In-Bombesin Conjugates for Prostate Cancer Imaging
- Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer
- Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention
- PET of Malignant Melanoma Using 18F-Labeled Metallopeptides
- Reducing Renal Uptake of Radiolabeled Peptides Using Albumin Fragments
- Bispecific Antibody Pretargeting of Radionuclides for Immuno-Single-Photon Emission Computed Tomography and Immuno-Positron Emission Tomography Molecular Imaging: An Update
- 64Cu-Labeled Tetrameric and Octameric RGD Peptides for Small-Animal PET of Tumor {alpha}v{beta}3 Integrin Expression
- Indication for Different Mechanisms of Kidney Uptake of Radiolabeled Peptides
- Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors
- Inhibition of Kidney Uptake of Radiolabeled Somatostatin Analogs: Amino Acids or Gelofusine?
- Reply: Inhibition of Kidney Uptake of Radiolabeled Somatostatin Analogs: Amino Acids or Gelofusine?